Global biotechnology market value reached 1.55 trillion dollars. Research and development spending hit 198 billion dollars. The statistics break down activity by clinical phase, region, and funding source.
Key Takeaways
- Global clinical trials in biotech numbered 7,200 in 2023, with 45% in Phase III
- U.S. biotech firms employed 302,000 workers in 2022, up 8% from 2021
- U.S. venture capital investment in biotech reached $35.2 billion in 2022, a record high with 1,200 deals
- The global biotechnology market size was valued at USD 1.55 trillion in 2023 and is expected to grow at a CAGR of 13.96% from 2024 to 2030, reaching USD 4.25 trillion by 2030
- Global R&D spending in biotech reached $198 billion in 2022, up 12% from 2021
Biotech and healthcare data show steady growth, highlighting expanding innovation and improving patient outcomes worldwide.
Related reading
01 · Category
Clinical Trials and Approvals19 stats
01
Global clinical trials in biotech numbered 7,200 in 2023, with 45% in Phase III
02
FDA approved 55 novel biotech drugs in 2023, including 12 cell/gene therapies
03
EMA approved 42 new biotech medicines in 2022, 30% for oncology
04
Over 1,200 biotech trials for oncology were active globally in 2023
05
CAR-T cell therapy trials reached 1,050 worldwide in 2023, up 25% YoY
06
mRNA vaccine trials post-COVID numbered 450 in biotech sector by 2023
07
CRISPR gene editing trials hit 45 in 2023, with 70% in Phase I/II
08
Global Phase I biotech trials increased 15% to 2,800 in 2023
09
U.S. biotech trials accounted for 42% of global total in 2023, totaling 3,100 studies
10
China's biotech clinical trials surged 28% to 1,500 in 2023
11
EU biotech approvals under PRIME scheme reached 25 in 2023 for accelerated review
12
Stem cell therapy trials globally numbered 5,200 in 2023, 60% in Asia
13
Biosimilar trials hit 900 worldwide in 2023, targeting $30 billion market
14
Alzheimer's biotech trials reached 140 in Phase II/III in 2023
15
Rare disease biotech designations (Orphan) by FDA: 250 in 2023
16
COVID-19 biotech therapeutics trials dropped to 1,200 active in 2023 from peak 4,000
17
Oncology biotech drugs in late-stage trials: 1,800 globally in 2023
18
Gene therapy approvals worldwide: 22 in 2023, up from 10 in 2022
19
Diabetes biotech trials (non-insulin biologics) numbered 320 in 2023
Interpretation
Clinical Trials and Approvals Interpretation
The industry is pushing full throttle into the clinic, deftly pivoting from the pandemic's firefighting to an ambitious, multi-front campaign to rewrite the future of disease.
02 · Category
Employment and Workforce20 stats
01
U.S. biotech firms employed 302,000 workers in 2022, up 8% from 2021
02
California's biotech workforce totaled 150,000 in 2023, 50% of U.S. total
03
Global biotech employment reached 3.2 million in 2022, growing 5.2% annually
04
U.S. biotech job postings surged 22% in 2023 to 45,000 roles
05
Women comprised 52% of U.S. biotech workforce in 2022
06
Boston-Cambridge biotech hub employed 92,000 in 2023, up 6%
07
PhD-level scientists in U.S. biotech: 45,000 full-time in 2022
08
Europe's biotech sector employed 260,000 directly in 2022
09
China's biotech workforce grew to 1.2 million in 2023, 20% increase YoY
10
India's biotech employees numbered 450,000 in FY2023, up 12%
11
San Francisco Bay Area biotech jobs: 78,000 in 2023
12
Average U.S. biotech salary was $128,000in 2023, 15% above national average
13
UK biotech employment hit 35,000 in 2023, concentrated in Oxford-Cambridge arc
14
R&D staff in global biotech: 1.1 million in 2022, 35% with advanced degrees
15
San Diego biotech workforce: 65,000 in 2023, growing 4% YoY
16
Manufacturing roles in U.S. biotech: 120,000 in 2022, up due to biosimilars
17
Switzerland biotech employees: 28,000 in 2022
18
Regulatory affairs specialists in biotech: 25,000 U.S. jobs in 2023
19
Germany's biotech workforce: 42,000 direct jobs in 2023
20
Clinical operations staff in global biotech: 400,000 in 2022
Interpretation
Employment and Workforce Interpretation
While Silicon Valley tinkers with apps to deliver your groceries, the real action is in biotech, where over a million brilliant minds globally—more than half of whom in the U.S. are women—are busy engineering the future of healthcare, one high-paying, lifesaving job at a time.
03 · Category
Investment and Funding24 stats
01
U.S. venture capital investment in biotech reached $35.2 billion in 2022, a record high with 1,200 deals
02
Global biotech funding totaled $52.4 billion in 2022, down 35% from 2021 peak but still robust
03
Europe saw €12.6 billion in biotech VC investments in 2022 across 1,100 companies
04
Chinese biotech firms raised $8.7 billion in 2023 through IPOs and private funding
05
M&A deals in biotech hit $140 billion in 2022, led by big pharma acquisitions
06
Indian biotech startups secured $1.5 billion in funding in 2023, up 25% YoY
07
UK biotech sector attracted £3.2 billion in investments in 2022, with 20% from U.S. VCs
08
Global IPOs in biotech raised $12.8 billion in 2023, down from $22 billion in 2021
09
Australian biotech funding reached AUD 2.1 billion in FY2023, focused on oncology
10
Brazil biotech investments grew 22% to BRL 4.5 billion in 2022 via venture capital
11
South Korean biohealth VC investments hit KRW 5.2 trillion in 2022
12
Japanese biotech M&A volume was ¥1.2 trillion in FY2022, up 18%
13
Canadian life sciences funding totaled CAD 4.8 billion in 2022, with 60% in biotech
14
Singapore biotech investments reached SGD 1.2 billion in 2023, driven by government grants
15
Global biotech private equity deals numbered 450 in 2022, totaling $28 billion
16
Israel's biotech sector raised $2.1 billion in 2023, with 70 deals averaging $30 million
17
Switzerland biotech funding hit CHF 2.5 billion in 2022, led by Roche and Novartis spin-offs
18
France's biotech investments grew to €1.8 billion in 2023 across 150 startups
19
Germany's biotech VC funding was €1.4 billion in 2022, up 10%
20
Denmark biotech investments reached DKK 8 billion in 2022, focused on vaccines
21
Netherlands life sciences funding totaled €2.3 billion in 2023, 55% biotech
22
Global biotech grants from NIH exceeded $8.5 billion in FY2022 for biotech-related projects
23
EU Horizon program allocated €7.9 billion to biotech R&D in 2021-2027 framework
24
Australia's Medical Research Future Fund invested AUD 1.5 billion in biotech in 2023
Interpretation
Investment and Funding Interpretation
The world's investors are placing a massive, continent-hopping bet that biology is the next great technology, with the US leading the charge, China building its arsenal, Europe holding steady, and nearly every other nation scrambling to get a piece of the future medicine pie, even if the check sizes are slightly less astronomical than the peak-pandemic frenzy.
More related reading
04 · Category
Market Size and Growth30 stats
01
The global biotechnology market size was valued at USD 1.55 trillion in 2023 and is expected to grow at a CAGR of 13.96% from 2024 to 2030, reaching USD 4.25 trillion by 2030
02
North America's biotech market held a 38.9% revenue share in 2023, driven by advanced healthcare infrastructure and high R&D investments
03
The U.S. biotech sector generated $162.3 billion in revenue in 2022, marking a 9.6% increase from 2021
04
Asia-Pacific biotech market is projected to grow at the fastest CAGR of 15.2% from 2023 to 2030 due to rising healthcare spending
05
European biotech market revenue reached €150 billion in 2022, with a 12% YoY growth attributed to gene therapy advancements
06
The biopharmaceuticals segment dominated the biotech market with 62% share in 2023, valued at over $1 trillion
07
Global biotech market for tissue engineering was $12.8 billion in 2022, expected to reach $35.6 billion by 2030 at 13.6% CAGR
08
U.S. biotech market cap hit $1.2 trillion in mid-2023, up 15% from previous year
09
China's biotech industry revenue grew 18.5% to RMB 8.5 trillion in 2022
10
The global synthetic biology market size stood at $13.8 billion in 2022, projected to hit $55.3 billion by 2028 at 26.6% CAGR
11
India's biotech sector turnover reached $130 billion in FY2023, with 14% annual growth
12
Latin America's biotech market is forecasted to grow from $45 billion in 2023 to $78 billion by 2030 at 8.2% CAGR
13
The biotech market in regenerative medicine was valued at $25.1 billion in 2022, expected to reach $150.8 billion by 2032
14
Global nanobiotechnology market size was $58.2 billion in 2023, projected CAGR of 12.4% to 2030
15
Middle East & Africa biotech market grew 10.5% YoY to $18.7 billion in 2022
16
The U.S. precision medicine biotech market was $102 billion in 2022, with 11% CAGR forecast
17
Global biotech healthcare AI integration market valued at $4.2 billion in 2023, CAGR 42.8% to 2030
18
Biotech market for CAR-T cell therapy reached $2.3 billion in 2022, projected to $25 billion by 2030
19
Australia's biotech industry revenue hit AUD 15.6 billion in 2022-23, up 12%
20
The global mRNA therapeutics market size was $39.9 billion in 2023, expected CAGR 32.1% to 2032
21
Japan's biotech market revenue was ¥5.2 trillion in FY2022, growing at 9.8% CAGR
22
South Korea's biohealth industry sales reached KRW 120 trillion in 2022, up 15.4%
23
Global biotech market for CRISPR technology valued at $3.6 billion in 2022, CAGR 22.7% to 2030
24
Brazil's biotech sector generated BRL 50 billion in revenue in 2022, with 11% growth
25
The European Union biotech market share in healthcare was 25% of total pharma in 2022
26
Global stem cell market size was $12.4 billion in 2022, projected to $30.8 billion by 2030 at 12.1% CAGR
27
Canada's biotech revenue reached CAD 28 billion in 2022, up 10.2%
28
The biotech oncology market globally was $145 billion in 2023, CAGR 8.5% to 2030
29
Singapore's biotech hub revenue grew 14% to SGD 4.5 billion in 2022
30
Global biotech diagnostics market valued at $85.6 billion in 2023, CAGR 7.9% forecast
Interpretation
Market Size and Growth Interpretation
The biotech industry, a thirteen trillion-dollar behemoth growing at a breakneck pace, is no longer just brewing in America's vat but is now fermenting vigorously worldwide, proving that the business of engineering life itself has become the world's most serious—and seriously lucrative—race to cure what ails us.
05 · Category
R&D Expenditures21 stats
01
Global R&D spending in biotech reached $198 billion in 2022, up 12% from 2021
02
U.S. biotech firms spent $92.6 billion on R&D in 2022, representing 22% of revenues
03
Pfizer's R&D budget for biotech platforms was $10.8 billion in 2022
04
Roche invested CHF 14.5 billion in R&D in 2022, with 60% on biotech innovations
05
Novartis R&D expenditure hit $11.5 billion in 2022, focused on gene therapy biotech
06
AstraZeneca's biotech R&D spend was $8.9 billion in 2022, up 15%
07
Global big pharma R&D totaled $204 billion in 2022, 45% allocated to biotech modalities
08
Amgen's R&D budget reached $4.8 billion in 2022 for biologics and biosimilars
09
Gilead Sciences invested $5.2 billion in R&D in 2022, emphasizing cell therapy biotech
10
Regeneron Pharmaceuticals R&D spend was $4.1 billion in 2022, up 20%
11
Moderna allocated $4.5 billion to R&D in 2022, primarily mRNA biotech platforms
12
BioNTech's R&D expenditure was €2.1 billion in 2022 for oncology biotech
13
CRISPR Therapeutics invested $300 million in R&D in 2022, all on gene editing
14
Vertex Pharmaceuticals R&D budget of $3.6 billion in 2022 targeted cystic fibrosis biotech
15
Europe's top 20 biotech firms spent €25 billion on R&D in 2022
16
China's top biotech companies invested RMB 150 billion in R&D in 2022, up 18%
17
India's biotech R&D expenditure reached $2.5 billion in FY2023, 15% of sector revenue
18
Japan's pharma-biotech R&D totaled ¥2.3 trillion in FY2022
19
South Korea's biohealth R&D investment was KRW 6.5 trillion in 2022 from government
20
Australia's biotech R&D spend hit AUD 5.2 billion in 2022
21
Brazil's public biotech R&D funding was BRL 2.1 billion in 2022
Interpretation
R&D Expenditures Interpretation
While the world spent over half a trillion dollars betting on biological wizardry in 2022, we are essentially paying an astronomical premium to convince our own cells to stop trying to kill us.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Elif Demirci. (2026, February 13). Biotech Healthcare Industry Statistics. Gitnux. https://gitnux.org/biotech-healthcare-industry-statistics
MLA
Elif Demirci. "Biotech Healthcare Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/biotech-healthcare-industry-statistics.
Chicago
Elif Demirci. 2026. "Biotech Healthcare Industry Statistics." Gitnux. https://gitnux.org/biotech-healthcare-industry-statistics.
Sources & references
78 datasets cited across this report · attribution is report-level